Sarepta Therapeutics, Inc.
SRPT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $399 | $611 | $745 | $658 |
| % Growth | -34.6% | -18% | 13.1% | – |
| Cost of Goods Sold | $151 | $153 | $138 | $132 |
| Gross Profit | $249 | $459 | $607 | $526 |
| % Margin | 62.2% | 75% | 81.5% | 79.9% |
| R&D Expenses | $219 | $204 | $773 | $200 |
| G&A Expenses | $92 | $138 | $134 | $164 |
| SG&A Expenses | $92 | $138 | $134 | $164 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $41 | $1 | $1 | $1 |
| Operating Expenses | $352 | $343 | $908 | $364 |
| Operating Income | -$103 | $116 | -$300 | $162 |
| % Margin | -25.9% | 18.9% | -40.3% | 24.6% |
| Other Income/Exp. Net | -$91 | $38 | -$83 | $10 |
| Pre-Tax Income | -$194 | $154 | -$384 | $172 |
| Tax Expense | -$14 | -$43 | $64 | $13 |
| Net Income | -$180 | $197 | -$448 | $159 |
| % Margin | -45.1% | 32.2% | -60.1% | 24.2% |
| EPS | -1.795 | 2.01 | -4.6 | 1.65 |
| % Growth | -189.3% | 143.7% | -378.8% | – |
| EPS Diluted | -1.795 | 1.89 | -4.6 | 1.5 |
| Weighted Avg Shares Out | 100 | 98 | 97 | 96 |
| Weighted Avg Shares Out Dil | 100 | 107 | 97 | 108 |
| Supplemental Information | – | – | – | – |
| Interest Income | $8 | $7 | $12 | $15 |
| Interest Expense | $8 | $5 | $5 | $4 |
| Depreciation & Amortization | $18 | $11 | $10 | $10 |
| EBITDA | -$168 | $170 | -$369 | $187 |
| % Margin | -42.1% | 27.8% | -49.5% | 28.4% |